Cambrian Bio Reports Positive Phase 1b ATX-304 Data
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK, N.Y. | June 18, 2026 Cambrian Bio has presented positive Phase 1b clinical data for ATX-304, the...
